- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT02738658
Comparison of the Vasomotor Function and Myocardial Flow in Patients Treated With Bioresorbable and Metallic Stents at 1 Year (BVS-Flow)
Comparison of the Vasomotor Function and Myocardial Flow in Patients Treated
Background: A total of 25-50% of patients with stable coronary atherosclerosis treated with metallic stent implantation remain with effort angina despite optimal medical treatment and absence of stent restenosis at 1 year. The most plausible cause of persistent effort angina after stent implantation is microcirculatory dysfunction. Coronary circulation matches the myocardial blood supply and oxygen consumption. Metallic stent implantation has been related with endothelial dysfunction and impaired coronary blood flow reserve (relation between coronary blood flow at rest and maximal hyperemia) of the treated vessel at 1 year.
Bioresorbable Vascular Scaffold (BVS) has been shown to improve the endothelial function and to improve the angina symptoms at 1 year. However, the coronary blood flow of BVS has never been tested.
Main objective: To determine differences in the blood average peak velocity at maximal hyperemia with adenosine infusion between patients treated with bioresorbable and metallic coronary stents at 1 year after stent implantation.
Methodology: A total of 70 patients are 1:1 randomized to everolimus-eluting metallic stent (EES) versus everolimus-eluting BVS implantation in patients with stable coronary disease. At 1 year, patients undergo to invasive coronary angiography prior cessation of vasomotor drugs. A pressure/Doppler wire is advanced distally to the "treated segment" and the endothelial (acetylcholine) and non-endothelial (adenosine and nitroglycerine) vasomotor function is assessed with quantitative coronary angiography and pressure and Doppler measurements. Angina test questionnaires are obtained at different time-points of the study.
Expected results: A difference between patients treated with BVS and EES of 12.0 cm/sc in the maximal average peak velocity (APV) under maximal hyperemia (with adenosine administration) is expected, as assessed by Doppler measurements, at 1 year after stent implantation. The study is powered to assess superiority in terms of maximal APV favoring patients treated with BVS.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Faktiske)
Fase
- Fase 4
Kontakter og plasseringer
Studiesteder
-
-
-
Barcelona, Spania, 08003
- Hospital del Mar
-
Barcelona, Spania, 08036
- Hospital Clinic
-
-
Barcelona
-
L´Hospitalet de Llobregat, Barcelona, Spania, 08173
- Hospital Universitari de Bellvitge
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Patients with stable angina or silent angina with myocardial ischemia detected by non-invasive tests or patients with acute coronary syndromes with no increase of > 5 times the upper value of normality of cardiac biomarkers (troponin).
- Patients with coronary artery disease with angiographic stenosis >
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Annen
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Enkelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: Bioresorbable vascular scaffold (BVS)
Patients with stable coronary angina with coronary artery disease suitable to be treated with a bioresorbable vascular scaffold.
|
Andre navn:
|
Aktiv komparator: Everolimus-eluting stent (EES)
Patients with stable coronary angina with coronary artery disease suitable to be treated with a Everolimus-eluting stent .
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Difference in the average peak velocity at maximal hyperemia between bioresorbable vascular scaffolds and everolimus-eluting stents as assessed by doppler wire measurement.
Tidsramme: 1-year after stent implantation
|
1-year after stent implantation
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Difference in endothelial dysfunction with acetyl-choline infusion between bioresorbable vascular scaffolds and everolimus-eluting stents as assessed by quantitative coronary angiography (4% of lumen reduction)
Tidsramme: 1-year after stent implantation
|
1-year after stent implantation
|
Andre resultatmål
Resultatmål |
Tidsramme |
---|---|
Difference in fractional flow reserve at maximal hyperemia between the two treatment groups as assessed by pressure-wire measurement
Tidsramme: 1-year after stent implantation
|
1-year after stent implantation
|
Samarbeidspartnere og etterforskere
Samarbeidspartnere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 20151810
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Bioresorberbart vaskulært stillas
-
Elixir Medical CorporationEuropean Cardiovascular Research CenterAvsluttet
-
Elixir Medical CorporationFullførtKoronararteriesykdomNew Zealand, Belgia
-
University Hospital, GenevaAvsluttet
-
Efemoral Medical, Inc.RekrutteringVaskulære sykdommer | Perifer arteriell sykdom | Stenose | Femoropoliteal stenoseNew Zealand, Australia
-
Biotronik AGUkjentKoronararteriesykdom | KoronararteriestenoseSpania, Danmark, Tyskland, Brasil, Belgia, Nederland, Singapore, Sveits
-
Shanghai MicroPort Medical (Group) Co., Ltd.Fullført
-
Abbott Medical DevicesFullført